<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895593</url>
  </required_header>
  <id_info>
    <org_study_id>FMT-CN-190321</org_study_id>
    <nct_id>NCT03895593</nct_id>
  </id_info>
  <brief_title>Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections</brief_title>
  <official_title>Rescue Fecal Microbiota Transplantation for Refractory Intestinal Infections: China National Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Suzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LiuZhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lishui Country People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Second Hospital of Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A national data registry of patients receiving the rescue fecal microbiota transplantation
      for the refractory intestinal infections from the Chinese fmtBank designed to assess the
      short-term and long-term safety and efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry will enroll national patients with refractory intestinal infections receiving
      rescue fecal microbiota transplantation (FMT) from the Chinese fmtBank, from September 2015
      to February 2019. Data of demographic characteristics, symptoms of intestinal infections,
      previous medicine treatment and clinical outcomes will be collected retrospectively
      abstracted from the electronic medical records. All the patients will be followed up for at
      least 12 weeks post-FMT. Information on follow-up will be designed to assess the short-term
      and long-term adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2015</start_date>
  <completion_date type="Anticipated">May 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>abdominal symptom outcomes</measure>
    <time_frame>1 week</time_frame>
    <description>Definitions used to classify response, nonresponse and exacerbation for the abdominal symptom outcomes are based on the physicians' holistic evaluation of patients' abdominal symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>survival outcome</measure>
    <time_frame>4 weeks</time_frame>
    <description>The survival outcome refers to the 4-week survival post-FMT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Unfavorable signs, symptoms, or major changes from pre-FMT laboratory test results.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Intestinal Infection</condition>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Antibiotic-associated Diarrhea</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>rescue fecal microbiota transplantation</intervention_name>
    <description>Fecal microbiota transplantation refers to the infusion of fecal microbiota from healthy donor into patients' gastrointestinal tract.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        National patients with refractory intestinal infections receiving rescue FMT from the
        Chinese fmtBank from September, 2015 to February, 2019 will be included
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: National patients with refractory intestinal infections receiving
        rescue FMT from the Chinese fmtBank from September 2015 to February 2019 will be included.

        -

        Exclusion Criteria: Patients will be excluded from the analysis if they are not followed up
        for at least 12 weeks post-FMT.

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>faming zhang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>faming zhang, MD,PhD</last_name>
    <phone>086-025-58509883</phone>
    <email>fzhang@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>bota cui, MD,PhD</last_name>
    <phone>086-025-58509884</phone>
    <email>cuibota@njmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faming Zhang, MD, PhD</last_name>
      <phone>086-25-58509883</phone>
      <email>fzhang@njmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://cmts.ydata.org</url>
    <description>China Microbiota Transplantation System</description>
  </link>
  <link>
    <url>http://www.fmtBank.org</url>
    <description>China fecal microbiota transplantation bank</description>
  </link>
  <reference>
    <citation>Zhang F, Cui B, He X, Nie Y, Wu K, Fan D; FMT-standardization Study Group. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018 May;9(5):462-473. doi: 10.1007/s13238-018-0541-8. Epub 2018 Apr 24. Review.</citation>
    <PMID>29691757</PMID>
  </reference>
  <reference>
    <citation>McDonald D, Ackermann G, Khailova L, Baird C, Heyland D, Kozar R, Lemieux M, Derenski K, King J, Vis-Kampen C, Knight R, Wischmeyer PE. Extreme Dysbiosis of the Microbiome in Critical Illness. mSphere. 2016 Aug 31;1(4). pii: e00199-16. doi: 10.1128/mSphere.00199-16. eCollection 2016 Jul-Aug.</citation>
    <PMID>27602409</PMID>
  </reference>
  <reference>
    <citation>Li Q, Wang C, Tang C, He Q, Zhao X, Li N, Li J. Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. Crit Care. 2015 Feb 9;19:37. doi: 10.1186/s13054-015-0738-7.</citation>
    <PMID>25881250</PMID>
  </reference>
  <reference>
    <citation>Litao G, Jingjing S, Yu L, Lei Z, Xiaona H, Zhijing Z. Risk Factors for Antibiotic-Associated Diarrhea in Critically Ill Patients. Med Sci Monit. 2018 Jul 18;24:5000-5007. doi: 10.12659/MSM.911308.</citation>
    <PMID>30020891</PMID>
  </reference>
  <reference>
    <citation>van Beurden YH, Nieuwdorp M, van de Berg PJEJ, Mulder CJJ, Goorhuis A. Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation. Therap Adv Gastroenterol. 2017 Apr;10(4):373-381. doi: 10.1177/1756283X17690480. Epub 2017 Feb 8. Review.</citation>
    <PMID>28491142</PMID>
  </reference>
  <reference>
    <citation>Wei Y, Yang J, Wang J, Yang Y, Huang J, Gong H, Cui H, Chen D. Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis. Crit Care. 2016 Oct 18;20(1):332.</citation>
    <PMID>27751177</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>May 12, 2019</last_update_submitted>
  <last_update_submitted_qc>May 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fecal microbiota transplantation</keyword>
  <keyword>intestinal infection</keyword>
  <keyword>Clostridium Difficile Infection</keyword>
  <keyword>Antibiotic-associated Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

